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http://dx.doi.org/10.1016/j.jaci.2014.12.1943Antibody conjugates bispecific for intercel-
lular adhesion molecule 1 and allergen prevent
migration of allergens through respiratory
epithelial cell layers
To the Editor:
It is becoming increasingly evident that intact epithelial barrier
function is important for preventing allergens to reach tissues
involved in allergic inflammation.1 Therefore it is tempting to
speculate that strategies that either strengthen epithelial barrier
function or prevent allergen from crossing the epithelium might
have therapeutic potential.
In this study we produced an antibody conjugate bispecific
for intercellular adhesion molecule 1 (ICAM1) and a major
respiratory allergen (ie, the major grass pollen allergen Phl p 2)2
termed P2/ICAM1 to investigate whether such a conjugate can
inhibit the migration of allergens through respiratory cell
layers and reduce the activation of the inflammatory cells
underneath.
ICAM1 was used as a target molecule to anchor allergen-
specific antibodies on human bronchial epithelial cells because it
is expressed on the surfaces of respiratory epithelial cells,
especially under inflammatory conditions, and has a low turnover
rate.3 Furthermore, ICAM1 is a major target molecule for cellular
entry of human rhinovirus (HRV) strains, which are implicated in
asthma exacerbations,4 and has been reported to be highly
expressed on the respiratory epithelium of allergic patients.5
Antibody conjugates were formed through streptavidin-biotin
coupling (ie, conjugation) by using different ratios of the individ-
ual components (P2/ICAM1: 1:1, 1:0.5, and 1:0.25; see the
Methods section in this article’s Online Repository at www.
jacionline.org). P2/ICAM1, but not a conjugate formed with a
Phl p 5–specific antibody, reacted specifically with recombinant
Phl p 2 and ICAM1, as shown by means of ELISA (see the
Methods section and Figs E1 and E2 in this article’s Online Repos-
itory at www.jacionline.org). Furthermore, P2/ICAM1 bound spe-
cifically to the respiratory epithelial cell line 16HBE14o- and
immobilized Phl p 2 on the cells, as shown by using
fluorescence-activated cell sorting (FACS) and immunofluores-
cencemicroscopy, respectively (Fig 1 and see theMethods section
and Fig E3 in this article’s Online Repository at www.jacionline.
org). Images in Fig 1 show colocalization (Fig 1,A, yellow, merge)
of Phl p 2 (red, Alexa Fluor 568) and P2/ICAM1 (green, Alexa
Fluor 488) on the cell surface. When either Phl p 2 (Fig 1, B) or
Phl p 2–specific rabbit antibodies (Fig 1,C) were omitted, no bind-
ing of Alexa Fluor 568 goat anti-rabbit IgG was observed. When
P2/ICAM1was added to the cells, it was detectedwithAlexa Fluor
488 goat anti-mouse IgG specific for aICAM1 mouse IgG (Fig 1,
A-C, green). When P2/ICAM1 was omitted, detection antibodies
did not bind (Fig 1, D). No cell staining was found when
only secondary antibodies were applied (data not shown).
P2/ICAM1 remained bound to 16HBE14o- cell surfaces for up
to 72 hours at 378C (see Fig E4 in this article’s Online Repository
at www.jacionline.org).
In a subsequent series of experiments, we demonstrated that
P2/ICAM1 can prevent the apical-to-basolateral penetration of
Phl p 2 but not of the birch pollen allergen Bet v 1, a similarly
FIG 1. Visualization of P2/ICAM1 and Phl p 2 on 16HBE14o- cells by means of immunofluorescence
microscopy. Images (A-D) show cells incubated with different combinations of reactants (left margin and
bottom), which were stained with Alexa Fluor 488–labeled anti-mouse antibodies (green, left column)
and Alexa Fluor 568–labeled anti-rabbit antibodies (red, middle column) to visualize aICAM1-mouse IgG
and Phl p 2, respectively. Nuclei were stained with 49, 6-Diamidino-2-Phenylinodole, Dihydrochloride
(blue), and merged images are shown in the right column. White bars 5 20 mm.
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cultured respiratory epithelial 16HBE14o- cells by using a
well-established Transwell culture system (Costar Corning
Incorporated, Corning, NY; see Figs E5 and E6 in this article’s
Online Repository at www.jacionline.org), as described in the
Methods section in this article’s Online Repository.6 In the exper-
imental Transwell model allergen concentrations were tested that,
according to studies analyzing the release of grass pollen aller-
gens during pollen seasons, might naturally occur on themucosa.7
Furthermore, we showed that P2/ICAM1 also reacted specifically
with natural grass pollen–derived Phl p 2 (data not shown).
In the Transwell experiments we found that the apical addition
of P2/ICAM1 prevented the penetration of Phl p 2 over the full
period of analysis (ie, for 72 hours) into the basolateral
compartment (see Fig E5, A, gray bars, 1) when compared
with conditions without addition of P2/ICAM1 (Fig E5 A, gray
bars,2). When Phl p 2 and P2/ICAM1 conjugates were omitted,
no Phl p 2 signal was detected (see Fig E5, A, no Phl p 2, 72
hours). Additionally, no relevant penetration of P2/ICAM1–Phlp 2 complexes into the basolateral wells was found (Fig E5, B,
gray bars, 1). The addition of the P2/ICAM1 conjugate alone
did not affect the integrity of the epithelial layers when resistance
was measured at 24, 48, and 72 hours (data not shown).
Finally, we tested whether a reduction of transepithelial
allergen migration by P2/ICAM1 has an effect on basophil
activation to assess the migration of Phl p 2, capable of activating
mast cells or basophils. Results from basophil activation tests (see
theMethods section and Fig E7 in this article’s Online Repository
at www.jacionline.org) performed with samples from 3 indepen-
dent Transwell experiments with basophils from 3 representative
allergic patients are shown in Fig 2. The extent of basophil activa-
tion induced with basolateral samples showed a significant and
consistent reduction for samples taken from cultures in which
P2/ICAM1 had been added to the apical compartments (Fig 2,
gray bars, 1) compared with those in which P2/ICAM1 conju-
gates had been omitted (Fig 2, gray bars, 2). This effect was
observed at each of the analyzed time points. Basophil activation
induced by samples taken from the apical compartments (Fig 2,
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FIG 2. Inhibition of transepithelial migration of Phl p 2 by P2/ICAM1
conjugates leads to decreased basophil activation with basolateral
samples. Samples obtained from apical and basolateral compartments
of Transwell cultures were incubated with blood samples from 3
patients allergic to Phl p 2 (A-C), and basophil activation was measured
by determining upregulation of the surface marker CD203c on basophils
by using flow cytometry. CD203c upregulation expressed as the
stimulation index is displayed on the y-axis. Results are means of
triplicates, and error bars indicate SDs. *P < .05, **P < .01, and
***P < .001, ANOVA and linear contrasts.
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tained with basolateral samples from cell-free preparations (Fig
2, no cells). Basophil activation was not observed when Phl p 2
was absent from the cultures (Fig 2, no Phl p 2). Concentrations
of soluble ICAM1 in 16HBE14o- cell cultures were around 1
ng/mL in apical wells and not detectable in basolateral wells in
the experiments and had no influence on allergen-induced baso-
phil activation (data not shown).
Our experiments thus demonstrate that it is possible to use
antibody conjugates bispecific for ICAM1 and a major respiratory
allergen to inhibit allergenmigration through respiratory cell layers
and to reduce the activation of inflammatory cells underneath.
Because increasing numbers of human high-affinity antibodies
specific for a large variety of clinically relevant allergens
are becoming available,8 it should be possible to engineer
recombinant bispecific antibody constructs for a variety of
respiratory allergens that can be combined to protect patients
against several different sources for which the major allergens
have been identified. The topical application of the conjugates
to target organs of allergic inflammation might help prevent
allergens from intruding into the tissues and, subsequently,
from inducing allergic inflammation and boosting allergen-
specific IgE responses. For example, the conjugates can be
administered to the nose, eyes, buccal mucosa, and eventually
lung to treat respiratory, conjunctival, and oral allergic symptoms.
Taking the finding into consideration that anti–ICAM1 anti-
bodies were shown to inhibit rhinovirus infections and HRV-
induced inflammation, one might also speculate that antibody
conjugates that are bispecific for ICAM1 and allergens might
have a synergistic protective effect in allergic patients with HRV-
induced asthma exacerbations.9
We thank Professor Dieter Gruenert from the University of California, San
Francisco, Mt Zion Cancer Center, for kindly providing the cell line
16HBE14o-.
Christoph Madritsch, PhDa
Julia Eckl-Dorna, MD, PhDb
Katharina Blatt, PhDc
Isabella Ellinger, PhDd
Michael Kundi, MD, PhDe
Verena Niederberger, MDb
Peter Valent, MDc
Rudolf Valenta, MDa
Sabine Flicker, PhDa
From athe Division of Immunopathology, Department of Pathophysiology and
Allergy Research, Center for Pathophysiology, Infectiology and Immunology;
bthe Department of Otorhinolaryngology; cthe Division of Hematology and
Hemostaseology, Department of Internal Medicine I; dthe Division of Cellular and
Molecular Pathophysiology, Department of Pathophysiology and Allergy Research,
Center for Pathophysiology, Infectiology and Immunology; and ethe Institute of
Environmental Health, Center of Public Health, Medical University of Vienna,
Vienna, Austria. E-mail: sabine.flicker@meduniwien.ac.at.
Supported by grants F4607, F4613, F4605 and F4611 of the Austrian Science Fund
(FWF).
Disclosure of potential conflict of interest: M. Kundi has received consultancy fees from
Baxter, GlaxoSmithKline, and Pfizer; has provided expert testimony for Ashcraft &
Gerel, LLP; has received research support from EU 7th FP (no. 226873); and has
received lecture fees and payment for development of educational presentations
from the Chamber of Physicians. V. Niederberger has received research support
from the Austrian Science Fund (FWF; SFB4613), has received consultancy fees
from Biomay AG, and has received fees for presentations from Thermo Fisher and
Bencard. R. Valenta has received research support from Thermo Fisher, Biomay
J ALLERGY CLIN IMMUNOL
VOLUME 136, NUMBER 2
LETTERS TO THE EDITOR 493AG, and the Austrian Science Fund (FWF; SFB4605) and has received consultancy
fees from Biomay AG. S. Flicker has received research support from the Austrian Sci-
ence Fund (FWF; SFB4607). The rest of the authors declare that they have no relevant
conflicts of interest.
REFERENCES
1. Holgate ST, Roberts G, Arshad HS, Howarth PH, Davies DE. The role of the
airway epithelium and its interaction with environmental factors in asthma patho-
genesis. Proc Am Thorac Soc 2009;6:655-9.
2. Flicker S, Steinberger P, Norderhaug L, Sperr WR, Majlesi Y, Valent P, et al.
Conversion of grass pollen allergen-specific human IgE into a protective IgG(1)
antibody. Eur J Immunol 2002;32:2156-62.
3. Hua S. Targeting sites of inflammation: intercellular adhesion molecule-1
as a target for novel inflammatory therapies. Front Pharmacol 2013;4:127.
4. Rosenthal LA, Avila PC, Heymann PW, Martin RJ, Miller EK, Papadopoulos NG,
et al. Viral respiratory tract infections and asthma: the course ahead. J Allergy Clin
Immunol 2010;125:1212-7.
5. Gorska-Ciebiada M, Ciebiada M, Gorska MM, Gorski P, Grzelewska-Rzymowska
I. Intercellular adhesion molecule 1 and tumor necrosis factor alpha in asthma and
persistent allergic rhinitis: relationship with disease severity. Ann Allergy Asthma
Immunol 2006;97:66-72.
6. Reisinger J, Triendl A, Kuchler E, Bohle B, Krauth MT, Rauter I, et al.
IFN-gamma-enhanced allergen penetration across respiratory epithelium augments
allergic inflammation. J Allergy Clin Immunol 2005;115:973-81.
7. Sch€appi GF, Taylor PE, Pain MC, Cameron PA, Dent AW, Staff IA, et al.
Concentrations of major grass group 5 allergens in pollen grains and atmospheric
particles: implications for hay fever and allergic asthma sufferers sensitized to
grass pollen allergens. Clin Exp Allergy 1999;29:633-41.
8. Gadermaier E, Levin M, Flicker S, Ohlin M. The human IgE repertoire. Int Arch
Allergy Immunol 2014;163:77-91.
9. Traub S, Nikonova A, Carruthers A, Dunmore R, Vousden KA, Gogsadze L, et al.
An anti-human icam-1 antibody inhibits rhinovirus-induced exacerbations of lung
inflammation. PLoS Pathog 2013;9:e1003520.
Available online March 11, 2015.
http://dx.doi.org/10.1016/j.jaci.2015.01.006
In vivo allergenic activity of a hypoallergenic
mutant of the major fish allergen Cyp c 1
evaluated by means of skin testingTo the Editor:
Fish represents oneof the important allergen sources responsible
for IgE-mediated food allergy.1 Although many food allergies
developed during childhood are frequently outgrown, allergy to
fish often remains persistent, even in adulthood.2 Parvalbumin, a
small calcium-binding protein, was identified as the major and
highly cross-reactive fish allergen.3 Parvalbumins from several
fish species have been produced as recombinant allergens, and in
particular, recombinant carp parvalbumin, rCyp c 1, was found
to contain the majority of fish-specific IgE epitopes and to show
broad cross-reactivitywith parvalbumins fromavariety offish spe-
cies.4 A hypoallergenic derivative of carp parvalbumin has been
developed for specific immunotherapy of fish allergy.5,6 The IgE
reactivity and ability of this protein to induce activation of patients’
basophils in vitro was reduced by introducing point mutations in
the calcium-binding domains of Cyp c 1. Furthermore, it was
shown that immunization of animals with the Cyp c 1 mutant
(mCyp c 1) induced IgG antibody responses specific for the
wild-typeCyp c 1 allergen (wtCyp c 1),which blocked IgE binding
toCyp c 1 in patientswithfish allergy. In this studywe analyzed the
in vivo allergenic activity of the Cyp c 1 mutant by comparing it
with the wild-type allergen regarding the induction of
immediate-type skin reactions in patients with fish allergy.
We investigated 12 children sensitized to fish who had
experienced grade 2 to 4 reactions according to the gradingsystem of Sampson7 that could be attributed to fish ingestion.
Table I provides their demographic and clinical characterization,
and Table E1 in this article’s Online Repository at www.
jacionline.org provides their serologic characterization. They
had positive skin prick test reactions to codfish, as well as sardine
extract (see Table E2 in this article’s Online Repository at www.
jacionline.org), and had IgE antibodies specific for codfish extract
and/or the major codfish and carp allergens Gad c 1 and Cyp c 1,
as determined by means of ImmunoCAP and ISAC chip (Thermo
Fisher, Uppsala, Sweden). Childrens’ IgE reactivities to other
allergens are shown in Fig E1 in this article’s Online Repository
at www.jacionline.org. Cyp c 1–specific IgE levels determined
by using ImmunoCAP ISAC measurements showed a good
correlation with Cyp c 1–specific IgE levels determined by means
of ImmunoCAP (R25 0.9558, see Fig E2 in this article’s Online
Repository at www.jacionline.org). We further tested the children
with fish allergy for IgE cross-reactivity using nitrocellulose-
blotted extracts from carp, cod, and tuna (see Fig E3 in this
article’s Online Repository at www.jacionline.org).3 All patients
reacted to natural Cyp c 1 at approximately 10 kDa, whereas only
10 of 12 patients reacted to Gad c 1, and only 5 of 12 patients
showed weak IgE reactivity to the major tuna allergen Thu a 1.
Recombinant wtCyp c 1 and mCyp c 1 were expressed in
Escherichia coli and purified to homogeneity, as previously
described (see Fig E4, A in this article’s Online Repository at
www.jacionline.org).4,5 mCyp c 1 showed strongly reduced IgE
reactivity when compared with wtCyp c 1, as determined by
means of IgE dot blotting in 12 patients with fish allergy (see
Fig E4, B). The reduction in IgE reactivity to mCyp c 1 was
measured by using a quantitative nondenaturing RAST-based
IgE assay in an additional 15 children, showing a mean reduction
of 79%6 17.2% (see Fig E5 in this article’s Online Repository at
www.jacionline.org).
Skin prick tests with natural allergen extracts and purified
wtCyp c 1 andmCyp c 1were done during regular follow-up visits
of the patients at the Allergy Department, 2nd Pediatric Clinic,
University of Athens, ‘‘P&AKyriakou’’ Children’s Hospital, with
approval of the Institutional Ethics Committee after written
informed consent was obtained from the parents and oral consent
was obtained from the subjects. Skin prick tests were performed
on forearms by using histamine hydrochloride (positive control),
physiologic saline (negative control), sardine extract, cod extract
(Stallergenes, Antony, France), and 4 concentrations (1, 4, 16, and
32 mg/mL) of purified wtCyp c 1 and mCyp c 1. In addition, 11
control children (7 male and 4 female; age, 6-12 years) sensitized
to various food allergens, inhaled allergens, or both typical for the
Mediterranean area other than fish were included. Wheal sizes
were determined by using digital planimetry (ImageJ software,
National Institutes of Health, open source). A wheal area of
greater than 7.1 mm2 (corresponding to a mean diameter of
>3 mm) was considered positive.
Codfish and sardine extract induced positive skin reactions in
each of the 12 patients, yielding mean wheal areas between 7.22
mm2 (patient 10) and 114.28 mm2 (patient 6; ie, codfish) or
between 30.46 mm2 (patient 1) and 116.38 mm2 (patient 2; ie,
sardine; for detailed results, see Table E2). Histamine-induced
positive reactions ranged from 16.52 mm2 (patient 10) to 59.29
mm2 (patient 6), whereas sodium chloride did not induce any
reactions in any of the tested children. Table E2 specifies skin
reactions to the 4 different concentrations of wtCyp c 1 and
mCyp c 1. Six patients had positive reactions to wtCyp c 1 at
METHODS
Antibodies and antibody conjugation
A Phl p 2–specific IgE Fab fragment was previously isolated from an
allergic patient, as described by Steinberger et al.E1 This Fab was
converted into a fully human IgG1 antibody
E2 and stably expressed in
CHO-K1 cells (Madritsch and Flicker, unpublished data). This Phl p
2–specific IgG1 was purified by means of Protein G affinity chromatography
(Thermo Fisher Scientific, Pierce, Rockford, Ill). The Phl p 2–specific IgG1
antibody was conjugated with Lightning-Link Streptavidin (Innova
Biosciences, Cambridge, United Kingdom). A Biotin-labeled ICAM1–
specific mouse IgG1 antibody was purchased from Abcam (Cambridge,
United Kingdom). Three different ratios (1:1, 1:0.5, and 1:0.25) of the Strep-
tavidin-labeled Phl p 2–specific human IgG1 and the Biotin-labeled ICAM1–
specific mouse IgG1 were coincubated for at least 1 hour at room temperature
to form a bispecific antibody conjugate, which was termed P2/ICAM1.
ELISA evaluation of the binding specificities of
P2/ICAM1 conjugates
ELISA plates (Nunc Maxi-Sorp, Roskilde, Denmark) were coated with
recombinant ICAM1 (R&D Systems, Minneapolis, Minn), recombinant Phl p
2 (5 mg/mL), and grass pollen extract containing 5 mg/mL natural Phl p 2 or
recombinant Phl p 5 as an unrelated control allergen (5 mg/mL; Biomay AG,
Vienna, Austria) in 100 mmol/L NaHCO3 (pH 9.6). Plates were incubated for
1 hour at 378C, washed twice with PBS containing 0.05% (vol/vol) Tween-20
(PBST), and saturated with PBST containing 3% (wt/vol) BSA. P2/ICAM1
(1 mg/mL) was applied overnight at 48C. Bound P2/ICAM1 was detected
either with horseradish peroxidase–conjugated rat anti-mouse IgG1 antibodies
(BD PharMingen, San Diego, Calif) or alkaline phosphatase–conjugated goat
anti-human F(ab9)2 antibodies (Pierce), both diluted 1:5000 in PBST
containing 1% (wt/vol) BSA. OD measurements were carried out on ELISA
reader Spectramax Plus (Molecular Devices, Sunnyvale, Calif) at 405 nm.
Results are means of triplicates. Error bars indicate SDs.
Flow cytometry
Aliquots of approximately 150,000 16HBE14o- cells were incubated
with 1 mg of P2/ICAM1 in 50 mL FACS buffer (PBS supplemented with 2%
wt/vol BSA) for 30 minutes on ice. After washing, aliquots of 1 mg Phl p 2 in
50mL FACS buffer were added, and cells were again incubated for 30minutes
on ice. After further washing, cells were incubated with Phl p 2–specific rabbit
antibodies and an Alexa Fluor 488–labeled goat anti-rabbit antibody (Molec-
ular Probes, Life Technologies, Eugene, Ore). Biotin-conjugated anti–ICAM1
antibody was visualized with streptavidin conjugated to Alexa Fluor 488
(Molecular Probes). 7-AAD dye (Beckman Coulter, Brea, Calif) was used for
staining of dead cells. Controls included the biotin-conjugated anti–ICAM1
antibody isotype control (mouse IgG1MOPC-21,Abcam) and the Phl p 2–spe-
cific antibody conjugated to streptavidin, followed by Phl p 2 and Phl p 2–spe-
cific rabbit antibodies. Cells were analyzed on a FC500 Flow Cytometer
(Beckman Coulter) counting at least 30,000 cells per sample in duplicates
and were evaluated with FlowJo software (version 7.2.5; TreeStar, Ashland,
Ore).
Immunofluorescence microscopy
16HBE14o- cells, which had been cultured as described,E3 were seeded
on ibiTreat tissue culture–treated m-dishes (Ibidi GmbH, Munich, Ger-
many) and grown for 2 days to approximately 50% confluence. Cells
were washed twice with PBS, cooled to 48C, and further processed at
48C unless stated otherwise. Antibody-allergen complexes were formed
by means of coincubation of 5 mg of P2/ICAM1 and 1 mg Phl p 2 in
300 mL PBS for 30 minutes at room temperature and subsequently incu-
bated with the cells at 48C for 30 minutes. For the time course (24-72
hours) immunofluorescence experiments shown in Fig E4, antibody-
allergen complexes were incubated with cells at 378C for 24, 48, and 72
hours. Unbound complexes were removed by washing with PBS, and cells
were then incubated with Phl p 2–specific rabbit antibodies diluted 1:1000
in PBS. Cells were washed with PBS and fixed with 4% formaldehyde so-
lution for 20 minutes at room temperature, and the remaining aldehyde
groups were quenched with 50 mmol/L ammonium chloride in PBS for
10 minutes. Unspecific binding sites were blocked with 10% goat serum
in PBS overnight at 48C. Alexa Fluor 488 goat anti-mouse IgG (Molecular
Probes) diluted 1:1000 in PBS containing 10% goat serum was added to
the cells for 1 hour at room temperature to detect cell-bound P2/ICAM1.
Phl p 2 bound to P2/ICAM1 was visualized with Alexa Fluor
568–labeled goat anti-rabbit IgG (Molecular Probes) applied at a dilution
of 1:1000 in PBS for 1 hour at room temperature. Finally, nuclei were
stained with 1 mg/mL 49, 6-Diamidino-2-Phenylinodole, Dihydrochloride
(Molecular Probes) in PBS. Cells were washed twice with PBS between
individual incubations. Staining with fluorescent antibodies alone was
done to assess background signals. Controls omitting either Phl p 2, Phl
p 2–specific rabbit antibodies, or P2/ICAM1 were included. Wide-field
fluorescence imaging of fixed cells was carried out with a Zeiss Axio
Observer Z1 inverted fluorescence microscope equipped with an oil
immersion 40 3 lens (Pan Apochromat, 1.4 NA; Carl Zeiss, Oberkochen,
Germany) and the Zeiss AxioVision Software package (release 4.8).
ELISA differentiating free Phl p 2 from
P2/ICAM1–bound Phl p 2 in culture samples
The Phl p 2–specific human IgG1 was coated (1 mg/mL in 100 mmol/L
NaHCO3 [pH 9.6]) on ELISA plates, which were washed and blocked, as
described above, tomeasure free Phl p 2 in culture samples. Phl p 2was then de-
tected with rabbit anti–Phl p 2 antibodies (1:1000).E4 Bound rabbit antibodies
were visualized with a horseradish peroxidase–conjugated donkey anti-rabbit
antibody diluted 1:2000 (GE Healthcare, Little Chalfont, United Kingdom).
Recombinant ICAM1 (1 mg/mL in 100 mmol/L NaHCO3 [pH 9.6]) was
coated on ELISA plates, which were washed and blocked, as described above,
to detect P2/ICAM1–bound Phl p 2. Cell-culture supernatants were applied,
and P2/ICAM1–bound Phl p 2 was detected with rabbit anti–Phl p 2
antibodies, as described above. Results represent means of duplicates, with
error bars indicating SDs.
The human sICAM1 Platinum ELISA (extra sensitive) from eBioscience
(Vienna, Austria) was used to measure levels of soluble ICAM1 in culture
samples.
Cell culture and Transwell experiments
The epithelial cell line 16HBE14o- derived from human bronchial surface
epithelial cellsE5,E6 was cultivated, as previously described.E3 Baseline trans-
epithelial electrical resistance ranged consistently from 110 to 120 U/cm2 for
Transwells filled with medium without cells and was measured with an ohm
voltmeter (Millipore, Bedford, Mass). When cells reached a transepithelial
electrical resistance value of 400 U/cm2 (baseline subtracted), IFN-g (50
ng/mL; PeproTech, Rocky Hill, NJ) was added in all cultures to allow detect-
able allergen migration. Aliquots of 5 mg of P2/ICAM1 (ratio 1:0.25) were
applied to the apical chambers for 3 hours at 378C. Supernatants were
removed, and 10 ng of Phl p 2 or 10 ng of Bet v 1 in 0.5 mL of medium
was added to the apical compartment for 20 to 72 hours at 378C. According
to the calculations of Sch€appi et al,E7 10 ng of allergen per well was supposed
to be an amount in the physiologic range. The effect of P2/ICAM1 on Phl p 2
apical-to-basolateral transepithelial migration was assessed by comparing P2/
ICAM1-1–treated wells with untreated control wells. In addition, the transmi-
gration of Phl p 2, as well as that of P2/ICAM1–bound Phl p 2, through Trans-
well membranes without cells was assessed. Samples from the apical and
basolateral compartments were tested for the presence of free Phl p 2, P2/
ICAM1–bound Phl p 2, or both by means of ELISA.
Basophil activation assays
Basophil activation was assessed in vitro by measuring upregulation of
CD203c expression. Heparinized blood from patients with grass pollen allergy
with IgE antibodies against Phl p 2 were obtained after informed consent was
given. Blood aliquots (90 mL) were incubated with either samples from
the Transwell experiments or for control purposes with an anti-IgE mAb
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(1 mg/mL; Immunotech, Vaudreuil-Dorion, Quebec, Canada) or PBS for
15 minutes at 378C. Allergen-induced upregulation of CD203c was calculated
from mean fluorescence intensities (MFIs) obtained with stimulated
(MFIstim) and unstimulated (MFIcontrol) cells and expressed as the stimula-
tion index (MFIstim/MFIcontrol).E8 Cells were analyzed by means of 2-color
flow cytometry on a FACScan (BD Biosciences, San Jose, Calif). The gating
strategy is shown in Fig E7.
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FIG E1. Reactivity of P2/ICAM1 with Phl p 2 and ICAM1 in ELISAs.
Conjugates formed with different ratios of anti–Phl p 2 and anti-ICAM1
(x-axes: P2/ICAM1, 1:1, 1:0.5, and 1:0.25), anti–Phl p 2 (aP2-IgG), or
anti–ICAM1 (aICAM1-IgG) alone were tested for reactivity with Phl p 2 (A)
or ICAM1 (B) and detected with anti-human F(ab9)2 antibodies (black
bars) or anti-mouse IgG (gray bars). OD values (y-axes) corresponding to
bound P2/ICAM1 conjugates are shown as means of triplicates 6 SDs.
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FIG E2. Binding of the bispecific antibody conjugates P2/ICAM1 and
P5/ICAM1 to the immobilized allergens Phl p 2 and Phl p 5 and
recombinant ICAM1 in ELISAs. Bound P2/ICAM1 and P5/ICAM1 were
detected with alkaline phosphatase–conjugated anti-human F(ab9)2
antibodies. Buffer containing 0.5% BSA was applied as a negative control
(buffer control). One representative experiment of 3 is shown.
J ALLERGY CLIN IMMUNOL
AUGUST 2015
493.e4 LETTERS TO THE EDITOR
 0 
 20 
 40 
 60 
 80 
 100 
 %
 o
f M
ax
 
100 101 102 103 100 101 102 103
 0 
 20 
 40 
 60 
 80 
 100 
 %
 o
f M
ax
 
100 101 102 103
 0 
 20 
 40 
 60 
 80 
 100 
 %
 o
f M
ax
 
100 101 102 103
 0 
 20 
 40 
 60 
 80 
 100 
 %
 o
f M
ax
 
 0  200 400 600 800  1000 
 100 
 101 
 102 
 103 
41.47% 40.62%
 0  200 400 600 800  1000 
 100 
 101 
 102 
 103 
55.24%
 0  200 400 600 800  1000 
 100 
 101 
 102 
 103 
P2/ICAM1
1:1
P2/ICAM1
1: 0.5
A
B
C
αP2 IgG
P2/ICAM1
1:1
P2/ICAM1
1: 0.5
P2/ICAM1
1: 0.25
D
αPhl p 2 abs αPhl p 2 abs αPhl p 2 abs
FSC FSC FSC
αP
hl
 p
 2
 a
bs
αP
hl
 p
 2
 a
bs
αP
hl
 p
 2
 a
bs
αICAM1 IgG Biotin
αPhl p 2 abs
Strep FITC
100 101 102 103
 0 
 20 
 40 
 60 
 80 
 100 
 %
 o
f M
ax
 
P2/ICAM1
1: 0.25
FIG E3. Detection of ICAM1 or P2/ICAM1–captured Phl p 2 on respiratory epithelial cells by using flow
cytometry. A, ICAM1 was detected on the surfaces of 16HBE14o- cells by using ICAM1–specific antibodies
(white graph) or an isotype control (gray graph). FITC, Fluorescein isothiocyanate. B, Cells preincubated
with different ratios of P2/ICAM1 (1:1; 1:0.5; and 1:0.25) and Phl p 2 were probed for cell-bound Phl p 2
with specific rabbit antibodies (white graphs) or the isotype control (gray graphs). C, Scatter plots
showing percentages of Phl p 2–reactive cells with 3 different ratios of P2/ICAM1. D, Cells incubated with
Phl p 2–specific human IgG1 antibodies, followed by Phl p 2 and Phl p 2–specific rabbit antibodies. One
representative experiment of 3 independent experiments is shown.
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FIG E4. Visualization of P2/ICAM1 and Phl p 2 on 16HBE14o- cells by using immunofluorescence
microscopy over a time course of 24 (A), 48 (B), and 72 (C) hours. Images showing cells incubated with
different combinations of reactants (left margin and bottom), which were stained with Alexa Fluor 488–
labeled anti-mouse antibodies (green, left column) and Alexa Fluor 568–labeled anti-rabbit antibodies
(red, middle column) to visualize aICAM1–mouse IgG and Phl p 2, respectively. Nuclei were stained with
49, 6-Diamidino-2-Phenylinodole, Dihydrochloride (blue), and merged images are shown in the right col-
umn. White bars 5 20 mm.
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FIG E4. (Continued).
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FIG E4. (Continued).
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FIG E5. Cell-bound P2/ICAM1 conjugates inhibit transepithelial migration
of Phl p 2. A, ELISA detection of free Phl p 2 in apical (black bars) and
basolateral (gray bars) compartments of cultured 16HBE14o- cell
monolayers that had been preincubated with (1) or without (2) P2/ICAM1
conjugates. Concentrations of free Phl p 2 corresponding to OD values (y-
axis) were measured at different time points (x-axis: 24, 48, and 72 hours)
in wells with or without cells (no cells). In the negative control Phl p 2
was omitted (no Phl p 2). B, Simultaneous detection of P2/ICAM1–Phl p 2
complexes in the same samples as in Fig E5, A. Shown is one of 3
independent experiments producing comparable results.
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FIG E6. Cell-bound P2/ICAM1 conjugates inhibit transepithelial migration of Phl p 2 (A) but not of the
unrelated allergen Bet v 1 (B). ELISA detection of free Phl p 2 (Fig E6, A) or free Bet v 1 (Fig E6, B) in apical
(black bars) and basolateral (gray bars) compartments of cultured 16HBE14o- cell monolayers that had been
preincubated with (1) or without (2) P2/ICAM1 conjugates. Concentrations of free Phl p 2 or Bet v 1
corresponding to OD values (y-axis) were measured at 72 hours in wells with or without cells (no cells).
In the negative control Phl p 2 was omitted (no Phl p 2). ***P < .001, significant difference.
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FIG E7. Basophils were detected on the basis of side-scatter characteristics
and expression of CD203c and analyzed with Paint-a-gate in the
FlowJo program. Basophils are defined as CD203c1 cells in all samples.
PE, Phycoerythrin; SSC, side scatter.
J ALLERGY CLIN IMMUNOL
VOLUME 136, NUMBER 2
LETTERS TO THE EDITOR 493.e11
